Canary Appoints Dr. Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of First-in-Class Dual Gene Silencing Therapy for Obesity

October 14, 2025
9:00 am

Renowned Cleveland Clinic cardiologist and lead author of the landmark SELECT trial joins Canary to advance CCT-217 into Phase 1 trials.

New York, October 14, 2025 – Canary Cure Therapeutics, a biotechnology company pioneering dual gene silencing therapies for obesity and metabolic disease, today announced the appointment of Dr. Michael Lincoff, MD as Chief Clinical Officer.

Dr. Lincoff is a an interventional cardiologist and Professor Emeritus of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and an internationally recognized authority in obesity and cardiometabolic research. As lead author and study co-chair of the SELECT trial, he has shaped global understanding of obesity treatment and its cardiovascular implications. He has also served as a chair and advisor to U.S. regulatory agencies, bringing deep experience in guiding innovative therapies through development.

In his new role, Dr. Lincoff will oversee the clinical strategy and execution of Canary’s lead program CCT-217, a dual gene silencing therapeutic that targets fat remodeling and energy expenditure. Unlike first-generation obesity drugs that primarily act through appetite suppression, CCT-217 is designed to reprogram white fat into energy-burning tissue, preserve lean muscle mass, and deliver long-lasting metabolic benefits.

“We are honored to welcome Dr. Lincoff to Canary. His unmatched expertise in obesity and cardiovascular medicine will be instrumental in advancing our mission to bring innovative therapies like CCT-217 to patients who urgently need better treatment options,” said Raj Reddy, Founder and Chief Executive Officer of Canary.

“Joining Canary at this pivotal moment is tremendously exciting,” said Dr. Michael Lincoff. “The science behind dual gene silencing has the potential to redefine obesity treatment by addressing the underlying biology of fat remodeling and energy expenditure. I look forward to helping guide these programs safely through clinical development.”

About Canary Cure Therapeutics

Canary Cure Therapeutics is a biotech pioneering innovative RNA interference (RNAi) therapies to address the root biology of obesity and metabolic disease. Canary is developing first-in-class therapies designed to deliver meaningful and durable outcomes for patients. The company’s lead program, CCT-217, is advancing into Phase 1 clinical development.

www.canarycure.com

Contact: Anna Wang – Chief Strategy Officer anna@canarycure.com

Recent Posts

Canary Appoints Dr. Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of First-in-Class Dual Gene Silencing Therapy for Obesity

Canary Cure’s Game-Changing Obesity Therapy Burns Fat and Protects Muscle

CCT-217: A Landmark Gene Silencing Therapeutic for Weight Loss That Enhances Lean Mass Composition, Reduces Visceral, Subcutaneous Fat and Restores Metabolic Health in Obesity through Browning

Canary’s First-in-class Dual RNAi Gene Silencing Offers a Novel Approach to Weight Loss and Metabolic Disease Management

Canary Cure Advances Novel siRNA Therapeutic Targeting Obesity into In Vivo Trials

Pioneering RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Canary Cure Therapeutics Inc’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized

Canary Appoints Dr. Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of First-in-Class Dual Gene Silencing Therapy for Obesity

Renowned Cleveland Clinic cardiologist and lead author of the landmark SELECT trial joins Canary to advance CCT-217 into Phase 1 trials.

Recent Posts

Quick Links

Useful Links

Quick Contact

Follow Us